Market Overview

Morning Market Movers

Related NBIX
Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health
What Should Biotech Investors Do Now?
Related EPZM
Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma
10 Biotech Stocks With Catalysts Coming Soon
Premarket Biotech Digest: Pump-And-Dumps, MannKind DTC Campaign, Opdivo ODD (Seeking Alpha)

Neurocrine Biosciences (NASDAQ: NBIX) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.

Epizyme (NASDAQ: EPZM) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.

Verso Paper (NYSE: VRS) rose 31.70% to $4.23 after the company announced its plans to acquire NewPage for $1.4 billion.

Stereotaxis (NASDAQ: STXS) shares jumped 19.26% to $4.77 after the company Stereotaxis completed the clinical trial of Vdrive with V-Loop.

Posted-In: market moversNews Intraday Update Markets Movers


Related Articles (NBIX + EPZM)

Get Benzinga's Newsletters